Corrigendum to: “Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized Patients” [Clin Ther 2024;46:778–784]
Essy Mozaffari(Gilead Sciences (United States)), Alpesh Amin(University of California, Irvine), Neera Ahuja(Palo Alto University), Aastha Chandak(University of Nebraska Medical Center), Jason F. Okulicz(Gilead Sciences (United States)), Heng Jiang, Andrew Ustianowski(North Manchester General Hospital), Mark Berry(Gilead Sciences (United States)), Christina G. Rivera(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
|Immunity|2016|1.2k
Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy
|New England Journal of Medicine|2013|358
Clinical Outcomes of Elite Controllers, Viremic Controllers, and Long‐Term Nonprogressors in the US Department of Defense HIV Natural History Study
|The Journal of Infectious Diseases|2009|305
Use of Mobile Health Applications for Health-Seeking Behavior Among US Adults
|Journal of Medical Systems|2016|220